글로벌 진료 시점 검사(POCT) 시장 – 2031년까지의 산업 동향 및 예측

진료 시점 검사(POCT) 시장 분석 및 규모

혈액학에서 진료소 검사(POCT)는 환자의 위치 또는 그 근처에서 다양한 혈액 매개변수를 빠르게 평가하는 데 중요한 역할을 합니다. 혈액학을 위한 POCT 장치를 사용하면 의료 전문가가 샘플을 중앙 실험실로 보낼 필요 없이 헤모글로빈 수치, 헤마토크릿, 백혈구 수와 같은 주요 매개변수를 측정할 수 있습니다. 이 기능은 특히 응급 상황, 중환자 치료 시설, 실험실 시설에 대한 접근이 제한될 수 있는 원격 또는 자원이 제한된 지역에서 매우 유용합니다. 신속한 혈액학 검사는 빈혈, 감염, 출혈 장애와 같은 상태를 진단하는 데 도움이 되므로 적절한 치료 및 관리 전략을 신속하게 시작할 수 있습니다.

글로벌 진료 시점 검사(POCT) 시장 규모는 2023년에 363억 9천만 달러로 평가되었으며, 2031년까지 808억 8천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

시장 정의

진료소 검사(POCT)는 의사의 진료실, 병원 또는 병상과 같이 환자 치료 장소 근처 또는 그 자리에서 시행하는 의료 진단 검사입니다. 빠른 결과를 제공하여 샘플을 중앙 실험실로 보낼 필요 없이 즉각적인 임상적 의사 결정을 내릴 수 있습니다. POCT 장치는 종종 휴대하기 편리하고 사용하기 쉬워 의료 전문가가 효율적이고 편리하게 검사를 실시할 수 있습니다. 일반적인 진료소 검사의 예로는 혈당 모니터링, 임신 검사, 신속 연쇄상구균 검사가 있습니다.

진료 시점 검사(POCT) 시장 동향

운전자

• Growing Technological Advancements Improving the Usability of Diagnostic Devices

Miniaturization of sensors, development of novel detection methods such as biosensors and microfluidics, and integration of wireless connectivity enhance the efficiency and accuracy of POCT devices. Furthermore, innovations in materials science and manufacturing techniques enable the production of cost-effective and robust point-of-care diagnostic solutions. These technological advancements empower healthcare providers with faster and more reliable diagnostic capabilities, leading to improved patient outcomes, reduced healthcare costs, and greater accessibility to testing in diverse clinical settings.

• Demand for Convenient Testing leads to the Rising Point of Care Technology in Various Medical Specialties

Patients and healthcare providers increasingly seek testing methods that offer quick results, allowing for immediate clinical decision-making and timely interventions. POCT devices fulfil this need by providing rapid diagnostics at or near the point of care, eliminating the time-consuming process of sending samples to centralized laboratories. This demand is particularly significant in emergency situations, critical care settings, and remote or resource-limited areas where access to laboratory facilities is limited. The convenience and efficiency offered by POCT devices enhance patient satisfaction, improve healthcare outcomes, and drive the adoption of these technologies in various medical specialties and settings.

Opportunities

• Increasing Prevalence of Chronic Diseases promotes the Adoption of POCT

As chronic conditions such as diabetes, cardiovascular diseases, and chronic respiratory disorders become more prevalent globally, there is a growing need for frequent monitoring and early detection of these conditions. POCT devices offer the advantage of providing rapid and convenient testing for various biomarkers associated with chronic diseases, enabling timely intervention and personalized treatment plans. It facilitates proactive disease management and reducing the burden on centralized healthcare facilities, POCT devices address the evolving healthcare needs of individuals with chronic conditions, thus driving market growth and adoption.

• Increasing Regulatory Support Providing Clear Standards for the Commercialization of POCT Devices

Well-defined regulatory frameworks ensure the safety, efficacy, and quality of POCT products, instilling confidence among healthcare providers and patients. Regulatory bodies such as the FDA in the United States and the European Medicines Agency (EMA) in Europe play crucial roles in streamlining the approval process for POCT devices, fostering innovation and market growth. Furthermore, regulatory support often includes expedited pathways for the approval of novel POCT technologies, encouraging manufacturers to invest in research and development efforts to bring innovative products to market more swiftly.

In response to the global burden of malaria highlighted by the WHO, well-defined regulatory frameworks, overseen by bodies such as the FDA and EMA, play a crucial role in expediting the approval of innovative point-of-care testing (POCT) devices for rapid and accurate diagnosis. This regulatory support not only ensures the safety and efficacy of POCT products but also fosters timely access to diagnostics, aiding in the effective management and control of malaria outbreaks worldwide.

Restraints/Challenges

• High Initial Investment Costs Pose Limitation for Point-of-Care Diagnostics Companies

Healthcare facilities also face substantial upfront expenses when purchasing POCT devices from these companies, along with additional costs for training staff, maintenance, and ongoing quality control. These costs may deter some healthcare providers, especially those in resource-constrained settings, from adopting POCT technologies developed by these companies. Furthermore, reimbursement policies and funding limitations may not adequately cover these initial investments, further limiting adoption and impacting the revenue potential of Point-of-Care diagnostics companies.

• Time Consuming Professional Training Limits the Growth of POCT

Extensive training necessary for healthcare professionals to proficiently operate POCT devices imposes significant time and resource constraints. This impediment slows down the adoption and expansion of POCT services within healthcare facilities. Moreover, the intricate nature of some POCT technologies demands specialized skills, exacerbating the training burden. Consequently, the market's potential for rapid growth is curtailed due to the limitations posed by the need for comprehensive and time-intensive training programs.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2023, Siemens Healthcare GmbH formed a collabortaion with Unilabs worth over USD 200 million. Under this agreement, Unilabs will acquire 400 laboratory analyzers, aimed at enhancing the infrastructure for patient care
• In July 2022, BioGX launched a CE-marked three-gene multiplex POC COVID-19 test, utilizing their highly effective Xfree direct sample testing chemistry. This test, incorporated in their Xfree COVID-19 Direct RT-PCR assay, received emergency clearance from the USFDA, offering efficient and accurate COVID-19 diagnosis
• In January 2022, Roche launched its Cobas Pulse System in selected countries with the CE Mark approval. This system represents Roche Diagnostics' latest advancement in linked point-of-care solutions for professional blood glucose management, offering enhanced convenience and efficiency in monitoring blood glucose levels
• In October 2021, Thermo Fisher Scientific obtained FDA Emergency Use Authorization (EUA) to conduct COVID-19 tests utilizing the Spectrum Solutions SpectrumDNA SDNA-1000 collection device. This high-throughput, automated testing system, integrated with the Amplitude Solution, introduces a novel saliva sample collection method, streamlining COVID-19 testing processes

Point-of-Care Testing (POCT) Market Scope

The market is segmented on the basis of product, technology, prescription, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Glucose Monitoring Products
• Cardiometabolic Testing Products
• Infectious Disease Testing Products
• Pregnancy and Fertility Testing Products
• Tumor/Cancer Marker Testing Products
• Urinalysis Testing Products
• Cholesterol Testing Products
• Hematology Testing Products
• Drugs-of-Abuse Testing Products
• Fecal Occult Testing Products
• Rapid Coagulation Testing
• Other POC Products

Application

• Blood Transfusion
• Cardiac Monitoring
• Coagulation
• Blood Glucose
• Haematology
• Non- Invasive SPO2 Monitoring
• Non- Invasive PCO2 Monitoring
• Whole Blood Analysis
• Vital Sign Monitoring
• Others

Platform

• Lateral Flow Assays/Immunochromatography Tests
• Dipsticks, Microfluidics
• Molecular Diagnostics
• Immunoassays

Prescription Mode

• Prescription-Based Testing
• OTC Testing

Testing Type

• Immunoassays
• Cell-Based Assays
• Nucleic Acid Amplification Testing
• Clinical Chemistry Assays
• and Hematology

 End-User

• Hospitals
• Clinics
• Laboratories
• Home Care
• Ambulatory Surgery Centers
• Others

Distribution Channel

• Direct Tender
• Retail Pharmacies

 Point-of-Care Testing (POCT) Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, technology, prescription, application, end-user and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America is expected to dominate the market primarily because of its widespread adoption of advanced technologies in healthcare. Additionally, the region benefits from favorable reimbursement policies that encourage the utilization of POCT devices. Moreover, North America enjoys a higher standard of living, which increases the affordability and accessibility of such advanced medical technologies for the population. These factors collectively contribute to North America's dominance in the POCT market. For instance, In April 2023, Abbott announced clearance from the U.S. FDA for the reader component of the FreeStyle Libre 3 integrated continuous glucose monitoring system, marking a significant advancement in diabetes management technology.

The Asia-Pacific is expected for significant growth, driven by escalating demand for advanced diagnostic solutions and a concurrent rise in per capita income across the region. As individuals in Asia-Pacific gain greater purchasing power, they are increasingly investing in cutting-edge healthcare technologies, including diagnostic options. This trend is anticipated to fuel robust expansion, positioning the region as a key player in the global healthcare market during the forecast period.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 시장에 대한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 진료 시점 테스트(POCT) 시장 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• BD(미국)
• 지멘스 헬스케어 프라이빗 리미티드(독일)
• Bio-Rad Laboratories, Inc. (미국)
• Danaher Corporation(미국)
• SEKISUI Diagnostics (미국)
• 트리니티 바이오텍(아일랜드)
• 비오메리유(프랑스)
• EKF 진단(독일)
• AccuBioTech Co., Ltd. (중국)
• Beckman Coulter, Inc. (미국)
• PTS 진단(미국)
• 노바 바이오메디컬(미국)
• Chembio Diagnostics, Inc. (미국)
• QuidelOrtho Corporation(미국)
• 시엔코 주식회사(미국)

SKU-3159